Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (1): 99-104    DOI: 10.31083/j.ceog.2020.01.5019
Original Research Previous articles | Next articles
Mechanism for ginsenoside Rh2-induced apoptosis of triple-negative breast cancer MDA-MB-231 cells
Y. Zeng1, , †*(), J. Mao2, †, X. Wang1, B. Yin1, Z. Shen3, C. Di4, W. Gu5, M. Wu2
1.Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
2.Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China
3.Medical Oncology of Zhangjiagang First People's Hospital, Zhangjiagang, China
4.Emergency Center, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
5.Department of Otorhinolaryngology, Zhangjiagang Hospital of Traditional Chinese Medicine, Zhangjiagang, China
Download:  PDF(1157KB)  ( 246 ) Full text   ( 8 )
Export:  BibTeX | EndNote (RIS)      

Objective: The authors aimed to explore the apoptosis of triple-negative breast cancer (TNBC) MDA-MB-231 cells induced by ginsenoside Rh2 and the underlying mechanism. Materials and Methods: Changes in the viability of MDA-MB-231 cells after treatment with 20 (S)-Rh2 and 20 (R)-Rh2 for 48 hours were detected by MTT assay. Changes in the morphology of cell nuclei were observed by DAPI staining. The expressions of caspase-3, caspase-9, cytochrome c, Smac, Bak, and Bax related to the mitochondrial pathway were detected by Western blotting. Results: 20 (S)-Rh2 inhibited the proliferation of MDA-MB-231 cells, but 20 (R)-Rh2 failed to do so. After treatment with 20(S)-Rh2 for two hours under visible light, they shrank and had incomplete morphology, whereas the morphology of control group hardly changed. Under UV light, the nuclei stained with DAPI were blue. After treatment with 20 (S)-Rh2 for one hour, the nuclei shrank and ruptured, and nearly 90% ruptured at two hours. In contrast, the nuclei of PBS control group remained intact. The activity of caspase-9 in MDA-MB-231 cells treated with 7.5 μg/mL 20 (S)-Rh2 was increased at 30 minutes, and gradually increased over extended time. Under identical conditions, the activity of caspase-9 in control group did not change significantly. Cytochrome c and Smac were released from mitochondria to the cytoplasm at one hour after treatment with 7.5 μg/mL 20 (S)-Rh2. However, such release was not detected in the control group. Bax was translocated after 30 minutes of treatment with 7.5 μg/mL 20 (S)-Rh2, which then gradually accumulated in mitochondria over time and peaked at two hours. The Bax expression in the entire cell lysate remained unchanged. The translocation of Bax was not detected in control group. Conclusion: 20 (S)-Rh2 evidently inhibited the proliferation of TNBC cell line MDA-MB-231. It killed the cells by inducing apoptosis, probably by activating the mitochondrial pathway.

Key words:  Ginsenoside Rh2      Triple-negative breast cancer      Mitochondrial pathway.     
Published:  15 February 2020     
*Corresponding Author(s):  Y. Zeng     E-mail:

Cite this article: 

Y. Zeng, J. Mao, X. Wang, B. Yin, Z. Shen, C. Di, W. Gu, M. Wu. Mechanism for ginsenoside Rh2-induced apoptosis of triple-negative breast cancer MDA-MB-231 cells. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 99-104.

URL:     OR

Figure 1.  — Viability changes of MDA-MB-231 cells after 48 hours of treatment with 20(S)-Rh2 and 20(R)-Rh2.

Figure 2.  — Morphological changes of MDA-MB-231 cells and nuclei after treatment with 7.5 µg/mL 20(S)-Rh2 for 0, 0.5, 1, and 2 hours. A: 20(S)-Rh2. B: PBS control.

Figure 3.  — Caspase-3 activity changes of MDA-MB-231 cells after drug treatment.

Figure 4.  — Caspase-9 activity changes of MDA-MB-231 cells after drug treatment.

Figure 5.  — Release of cytochrome c and Smac from MDA-MB-231 cells after drug treatment.

Figure 6.  — Bax and Bak expressions in mitochondria and whole cell lysate of MDA-MB-231 cells after drug treatment.

[1] Lawson D.A., Bhakta N.R., Kessenbrock K., Prummel K.D., Yu Y., Takai K., et al.: “Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells”. Nature, 2015, 526, 131.
[2] Early Breast Cancer Trialists’ Collaborative Group: “Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level metaanalysis of the randomised trials”. Lancet, 2015, 386, 1341.
[3] Early Breast Cancer Trialists’ Collaborative Group: “Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials”. Lancet, 2015, 386, 1353.
[4] Nagata T., Shimada Y., Sekine S., Hori R., Matsui K., Okumura T ., et al.: “Prognostic significance of NANOG and KLF4 for breast cancer”. Breast Cancer, 2014, 21, 96.
[5] Krishnaraj C., Muthukumaran P., Ramachandran R., Balakumaran M.D., Kalaichelvan P.T.: “Acalypha indica Linn: biogenic synthesis of silver and gold nanoparticles and their cytotoxic effects against MDA-MB-231, human breast cancer cells”. Biotechnol. Rep., 2014, 4, 42.
[6] Tsai P.C., Fu Y.S., Chang L.S., Hsu S.C.N., Lu T.: “Cardiotoxin III suppresses HGF-and EGF-induced EMT and signaling network in breast cancer MDA-MB-231 cells”. FASEB J., 2017, 31, 879. 3.
[7] Lee H., Lee S., Jeong D., Kim S.J. : “Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells”. J. Gins. Res., 2018, 42, 455.
[8] Wen X., Zhang H.D., Zhao L., Yao Y.F., Zhao J.H., Tang J.H.: “Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer”. Asian Pac. J. Cancer Prev., 2015, 16, 1105.
[9] Xie X., Hu Y., Xu L., Fu Y., Tu J., Zhao H ., et al.: “The role of miR125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer”. Tumor Biol., 2015, 36, 7185.
[10] Sharifi S., Barar J., Hejazi M.S., Samadi N.: “Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel”. Asian Pac. J. Cancer Prev., 2014, 15, 8617.
[11] Hecht F., Pessoa C.F., Gentile L.B., Rosenthal D., Carvalho D.P., Fortunato R.S.: “The role of oxidative stress on breast cancer development and therapy”. Tumor Biol., 2016, 37, 4281.
[12] Padgaonkar A., Cosenza S., Pallela V., DRC V.S., Reddy M.V.R., Reddy E.P.: “The dual CK2/TNIK inhibitor, ON108600 targets cancer stem cells and induces apoptosis of paclitaxel resistant triplenegative breast cancer cells”. Am. Assoc. Cancer Res., 2015, 75, 4453.
[13] Sharifi S., Barar J., Hejazi M.S., Samadi N.: “Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Adv. Pharm. Bull., 2015, 5, 351.
[14] Allensworth J.L., Sauer S.J., Lyerly H.K., Morse M.A., Devi G.R.: “Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism”. Breast Cancer Res. Treat., 2013, 137, 359.
No related articles found!
No Suggested Reading articles found!